mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge.

mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge.

Publication date: Sep 22, 2023

The recent outbreaks of mpox have raised concerns over the need for effective vaccines. However, the current approved vaccines have either been associated with safety concerns or are in limited supply. mRNA vaccines, which have shown high efficacy and safety against SARS-CoV-2 infection, are a promising alternative. In this study, three mRNA vaccines are developed that encode monkeypox virus (MPXV) proteins A35R and M1R, including A35R extracellular domain -M1R fusions (VGPox 1 and VGPox 2) and a mixture of encapsulated full-length mRNAs for A35R and M1R (VGPox 3). All three vaccines induce early anti-A35R antibodies in female Balb/c mice, but only VGPox 1 and 2 generate detectable levels of anti-M1R antibodies at day 7 after vaccination. However, all three mRNA vaccine groups completely protect mice from a lethal dose of vaccinia virus (VACV) challenge. A single dose of VGPox 1, 2, and 3 provide protection against the lethal viral challenge within 7 days post-vaccination. Long-term immunity and protection were also observed in all three candidates. Additionally, VGPox 2 provided better passive protection. These results suggest that the VGPox series vaccines enhance immunogenicity and can be a viable alternative to current whole-virus vaccines to defend against mpox.

Open Access PDF

Concepts Keywords
A35r A35r
Days Alternative
Lethal Challenge
Monkeypox Concerns
Vaccines Current


Type Source Name
disease VO Monkeypox virus
disease VO Vaccinia virus
disease VO effective
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccination
disease VO vaccine
disease VO dose
drug DRUGBANK Tropicamide
disease VO viable
disease VO Variola virus
disease MESH smallpox
disease VO organization
disease MESH emergency
disease MESH infections
disease VO ACAM2000
disease VO company
disease VO Canada
drug DRUGBANK Coenzyme M
disease IDO cell
disease IDO host
disease VO Glycoprotein
drug DRUGBANK Alteplase
disease VO immunized
disease IDO production
disease IDO infection
drug DRUGBANK Aspartame
disease IDO blood
drug DRUGBANK Sodium lauryl sulfate
disease MESH vaccinia
disease IDO immune response
disease VO vaccinated
disease VO intranasal route

Original Article

(Visited 1 times, 1 visits today)